CIPLA MEDPRO SOUTH AFRICA LIMITED - Trading statement and clarification of results

Trading statement and clarification of results

CIPLA MEDPRO SOUTH AFRICA LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2002/018027/06)
(ISIN Number: ZAE000128179 Share Code: CMP)
("Cipla Medpro" or "the Company")


TRADING STATEMENT AND CLARIFICATION OF RESULTS

In terms of the JSE Limited Listings Requirements, companies are required to publish a trading statement as
soon as they are reasonably certain that the financial results for the current reporting period will be more
than 20% different from those of the previous corresponding period.

We refer to the trading statement issued by Cipla Medpro on 7 March 2013. Accordingly, shareholders are
now advised that the Company expects earnings per share (EPS) and headline earnings per share (HEPS) for
the 12 months ended 31 December 2012 to be between 35% and 45% lower than EPS and HEPS for the
prior corresponding period as reported in our 2011 integrated annual report.

Shareholders are further advised that our 2011 annual results as contained in our 2011 integrated annual
report are required to be restated and EPS and HEPS will be impacted due to the following:

      - incorrect application of our accounting policy on intangible assets in the past which has resulted in
        an annual amortisation charge and impairments in 2012 as well as a prior period restatement
        relating to historic amortisation charges and impairments of certain intangible assets; and

      - overstatement of stock.

The effect on the statement of comprehensive income for 2011, before tax, as a result of the items above is
noted in the table below:

                                                         2011
                                                        R’000
Impairment of intangible assets                       (18,142)
Amortisation of intangible assets                     (22,971)
Adjustments to stock                                  (25,654)

Accordingly, shareholders are advised that the Company expects EPS and HEPS for the 12 months ended 31
December 2012 to be between 25% and 35% lower than EPS and HEPS as per the restated 2011 annual
results.

The information in this trading statement has not been reviewed or reported on by Cipla Medpro's
auditors. The Company's results for the 12 months ended 31 December 2012 are expected to be published
on or about 26 March 2013 and additional details relating to the restatement of the 2011 results will be
provided therein.

15 March 2013
Bellville

Sponsor
Nedbank Capital

Date: 15/03/2013 03:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.